Grünenthal is a global leader in pain management. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

A mix of strong entrepreneurial spirit, close collaboration, and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

We believe compliance, ethics and transparency go hand in hand. Excellence in this area is a key topic for us – and is deeply anchored in our culture.

... Compliance and transparency

Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Partnering

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

Being a responsible corporate citizen means operating our business legally, ethically, respectfully and sustainably. All business areas collaborate cross-functionally to manage environmental, social and governance (ESG) risks and make a net-positive impact in our focus areas of Patient, People and Planet.

... Responsibility

At Grünenthal, our vision of a World Free of Pain aligns seamlessly with our commitment to sustainability, especially the social aspect. We regularly evaluate our products, services, and markets to ensure alignment with our sustainability objectives.

... Our responsibility approach

Grünenthal’s focus on patients is at the core of our responsibility approach. We concentrate our efforts on the key areas of patient safety, product quality, improving patients’ quality of life through innovative medicines, access to healthcare and safe pain management through the responsible use of opioids.

... Patient

How can we have a positive impact on the lives of the people we work with, our partners and wider society? Find out what we do to foster trust and promote diversity and inclusion, how we empower our employees to be their best and look after their health and wellbeing, and how we contribute to improving the quality of life for people and communities around us.

... People

We join together with our employees, partners and customers to reduce our carbon footprint, save energy and resources, and decrease waste in our value chain.

... Planet

The Grünenthal Responsible Sourcing Programme will increase transparency and help create a positive ESG impact in our supply chain and connected local communities.

... Responsible sourcing

... Corporate Citizenship

... Thalidomide

Our company has a clear vision of a world free of pain and we maintain a laser-sharp focus on this vision in everything we do – especially in our research and development activities.

... Science

We follow a holistic and solution-agnostic approach to deliver highly effective pain treatments, building our programmes on a firm foundation of human pathophysiology and solid human target validation.

... R&D approach

... Collaboration

To move closer to our vision of a world free of pain, we are currently pursuing a range of programmes across different modalities, targets and mechanisms of action.

... Pipeline

As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available.

... Clinical trials

Explore our media section and access a range of materials relating to our company.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2019 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

Working towards a world free of pain

Working towards a world free of pain

Matthew Loder, Sourcing Manager Warehousing and Logistics

Anne Severich, Manager Global Graduate Programme

Felipe Furiati, Head SRT Patches Lead

Our company has a clear vision of a world free of pain and we maintain a strong focus on this vision in everything we do in our research and development activities.

As a global leader in pain research and development, we are passionate about exploring innovative treatment options that have the potential to meaningfully improve the lives of patients around the world. Every day, Grünenthal’s scientists use their deep expertise to reimagine the future of pain management.

Executing our strategy, we focus our R&D efforts on pain, epilepsy, pruritus and neurodegenerative disorders - areas of high unmet medical need. We take a holistic approach to pursuing breakthrough treatments for these pain conditions – and explore all possible technologies and modalities. This enables us to pursue our priorities with a solution-agnostic mindset. We focus our in-house capabilities on critical and differentiating areas such as target identification, with a strong emphasis on human and clinical validation, as well as translational science and disease understanding. While focusing on these specific critical success factors, we are able to cover every step in the development of an innovative medicine. At the same time, we are committed to entering into strategic partnerships with innovative players from across industry and academia who share our passion for shaping the field and fostering the development of meaningful therapies.

“We are committed to developing innovative treatment options for patients with pain. Together with my team, I strive to bring the best science forward.”

Uli Brödl, MD,

Head of R&D, Chief Scientific Officer